Partner with DIFF Biotech, a clinical-stage biotechnology company developing next-generation vaccines and oncolytic virotherapy through proprietary viral engineering technologies.

 

Built on our Viraltech Architect Platform, DIFF Biotech integrates rational virus design, advanced molecular engineering, translational research and in vivo efficacy evaluation capabilities to accelerate the discovery and development of innovative biologics.

 

With a differentiated pipeline spanning human vaccines, veterinary vaccines and oncolytic virotherapy, we are advancing novel solutions to address unmet medical needs and emerging infectious disease challenges.

 

We collaborate with global pharmaceutical and biotechnology partners through flexible partnership models, including asset licensing, co-development and strategic research collaborations, enabling partners to access innovative technologies, expand pipeline opportunities and accelerate product development.

 

Why partner with DIFF Biotech?

 

• Proprietary viral engineering platform enabling differentiated biologics development
• Innovative pipeline across human and animal health applications
• Integrated discovery, preclinical evaluation and translational development capabilities
• Flexible partnership models tailored to global development strategies

 

 

Partnership Opportunities

 

01 Asset Licensing

 

DIFF Biotech has established a differentiated pipeline of innovative vaccine candidates and oncolytic virotherapy based on our proprietary viral engineering technologies.

 

We are actively seeking regional and global licensing partnerships with pharmaceutical and biotechnology companies that have complementary capabilities in clinical development, manufacturing, regulatory affairs, and commercialization.

 

Through strategic licensing collaborations, partners can access innovative assets with differentiated mechanisms, strong development potential, and opportunities for global expansion, while DIFF Biotech continues to provide scientific and translational support throughout product advancement.

 

Partnership opportunities include:

• Regional or global licensing of innovative vaccine and oncolytic virotherapy assets
• Strategic collaborations to accelerate clinical development and commercialization
• Co-commercialization opportunities in selected markets

 

02 Co-Development Partnerships

 

DIFF Biotech welcomes strategic collaborations with pharmaceutical and biotechnology companies seeking to develop next-generation vaccines and oncolytic virotherapy.

 

By combining DIFF Biotech’s proprietary viral engineering technologies and preclinical development expertise with partners’ strengths in clinical development, manufacturing, regulatory affairs and commercialization, we aim to accelerate innovative biologics from discovery toward global markets.

 

Our co-development model enables:

1）Complementary scientific and development expertise

2）Shared investment and risk management across development stages

3）Accelerated advancement of promising biologics programs

4）Enhanced global development and commercialization opportunities

 

03 Technology & Research Collaborations

 

Beyond pipeline-based partnerships, DIFF Biotech offers technology-enabled research collaborations to support innovation in vaccine development and antiviral drug discovery.

 

Leveraging our proprietary viral engineering platforms, antiviral screening technologies, and translational evaluation models, we collaborate with partners across early discovery, candidate validation, and preclinical development stages.

 

Our capabilities include:

• Viral construction and rational engineering
• Antiviral screening and mechanism-of-action evaluation
• Vaccine candidate assessment and immune evaluation
• In vivoefficacy studies
• Translational research support

 

Through collaborative research models, DIFF Biotech helps partners improve R&D efficiency, accelerate discovery timelines, and advance promising biologics toward clinical development.

 

Partner with DIFF Biotech

 

Together with global pharmaceutical and biotechnology leaders, DIFF Biotech aims to accelerate the development of transformative vaccines, oncolytic virotherapy and antiviral therapeutics that address critical global health challenges.